natgillin/translations-raw huggingface dataset:
The method of claim 1 wherein water content has been added to the waste in order to achieve an appropriate non-water content. The method of claim 4 wherein an appropriate non-water content is achieved by adding to the MSW a constant mass ratio of water between 0.5 and 2.5 kg water per kg MSW. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se otpadu dodaje sadržaj vode kako bi se postiglo prikladan sadržaj nevodenih tvari, i/ili što se prikladan sadržaj nevodenih tvari postiže dodavanjem u MSW konstantnog masenog omjera vode između 0,5 i 2,5 kg vode po kg MSW.
Other drawbacks related to the use of hard gelatine capsules for inhalation powders are (a) poor protection against moisture uptake from the ambient air, (b) problems with opening or perforation after the capsules have been exposed previously to extreme relative humidity, which causes fragmentation or indenture, and (c) possible inhalation of capsule fragments. 
Ostali nedostaci povezani s uporabom kapsula od tvrde želatina za prašak za inhaliranje su (a) slaba zaštita od povlačenja vlage iz okolnog zraka, (b) problemi kod otvaranja ili perforacije nakon što je kapsula u prethodnoj uporabi bila izložena ekstremnoj relativnoj vlažnosti, što može dovesti do fragmentacije ili ureza te (c) mogućnost inhalacije djelića kapsule.
A method as claimed in any of Claims 1 to 5 wherein the binding affinity of the mutant for the selected ligand is substantially the same or greater than the binding affinity of the parent for the selected ligand. 
Metoda iz Zahtjeva 1-5 naznačena time da je sklonost vezanju mutacije na odabrani ligand u bitnome jednaka ili veća od sklonosti vezanju izvora na odabrani ligand.
Pipeline pressure device according to one of the preceding claims, wherein the longitudinal part of the endless conveyor member has a length of at least 0.6 m at the side of the feed-through opening. 
Cjevovodni tlačni uređaj, prema jednom od prethodnih zahtjeva, naznačen time da uzdužni dio (5') beskonačnog transportnog člana (5) ima dužinu od najmanje 0,6 m na strani od provodnog otvora.
represents a C1-6 alkyl group, a C1-6 haloalkyl group, a C2-6 alkenyl group, a C3-8 cycloalkyl group, a hydroxyl group, a C1-6 alkoxy group, or a halogeno group, R5 represents a C1-6 alkyl group, a C1-6 haloalkyl group, a C6-10 aryl C1-6 alkyl group, a C3-8 cycloalkyl group, a C6-10 aryl group, a C1-7 acyl group, a C1-6 alkoxycarbonyl group, a C1-6 alkoxy group, an amino group, a mono C1-6 alkylamino group, di C1-6 alkylamino group, a C1-6 alkoxycarbonylamino group, a C1-6 alkylthio group, a C1-6 alkylsulfonyl group, a halogeno group, a cyano group or a nitro group, Y and Z are both carbon atom, D is an aromatic ring which includes both Y and Z, and X represents an oxygen atom. 
predstavlja skupinu C1-6 alkil, skupinu C1-6 haloalkil, skupinu C2-6 alkenil, skupinu C3-8 cikloalkil, hidroksilnu skupinu, skupinu C1-6 alkoksi, ili halogenu skupinu, predstavlja skupinu C1-6 alkil, skupinu C1-6 haloalkil, skupinu C6-10 aril C1-6 alkil, skupinu C3-8 cikloalkil, skupinu C6-10 aril, skupinu C1-7 acil, skupinu C1-6 alkoksikarbonil, skupinu C1-6 alkoksi, amino skupinu, skupinu mono C1-6 alkilamino, skupinu di C1-6 alkilamino, skupinu C1-6 alkoksikarbonilamino, skupinu C1-6 alkiltio, skupinu C1-6 alkilsulfonil, halogenu skupinu, cijano skupinu ili nitro skupinu, Y i Z su oba ugljikov atom, D je aromatski prsten koji sadrži oba Y i Z, i X predstavlja kisikov atom.
an intra prediction unit (150) configured to determine an intra prediction mode, to generate reference pixels corresponding to unavailable reference pixels, to adaptively filter the reference pixels according to the intra prediction mode, and to generate a prediction block using the reference pixels determined by the intra prediction mode; 
dekoder rezidualnog signala (220) konfiguriran za vraćanje rezidualnog signala pomoću intrapredikcijskog režima; generator referentnih piksela (240) konfiguriran za generiranje referentnih piksela koji odgovaraju nedostupnim referentnim pikselima i za adaptivno filtriranje referentnih piksela u skladu s intrapredikcijskim režimom;
A pharmaceutical composition comprising a compound of claim 1, or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient. 
Farmaceutski preparat koji sadrži spoj prema patentnom zahtjevu 1, ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljiv nosač, razblaživač ili ekscipijens.
Alternate Sidechain Coupling Reaction As illustrated above in the second reaction step of the alternative process of forming 7,9 acetal linked analogs of 9,10-aa OH taxanes, the C7,C10 di-CBZ 10-deacetylbaccatin Ill of Formula 35 was coupled with a sidechain of Formula 36 to form Formula 37. 
Kao što je gore prikazano u drugom koraku reakcije alternativnog postupka formiranja 7,9 acetalno povezanih analoga 9,10-aa OH taksana, C7, C10 di-CBZ 10-deacetilbakatin III formule 35 je bio spojen s bočnim lancem formule 36 da bi se formirala formula 37.
A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1 and, optionally, an effective amount of another therapeutic agent. 
Farmaceutski pripravak naznačen time da sadrži učinkovitu količinu spoja prema zahtjevu 1 ili zahtjevu 20 ili njegovu farmaceutski prihvatljivu sol za uporabu kod liječenja boli, uriname inkontinencije, čira, sindroma iritabilnog crijeva ili upalnog poremećaja crijeva. Farmaceutski pripravak prema zahtjevu 40, naznačen time da pripravak sadrži učinkovitu količinu drugog terapeutskog sredstva.
The aqueous component is then added with stirring to provide 10 mL of the I.V. 
Zatim se uz miješanje doda vodena komponenta kako bi se dobilo 10 ml i.v.
from 20% to 90% by weight of plaster, 
(a) od 20 do 90% po masi gipsa,
A compound according to claim 10 wherein the portion R1-A-NR2R3 of the compound is represented by the formula R1-X-(CH2)n NR2R3 where X is attached to the group E and is a group CH, and n is 2. 
Spoj prema zahtjevu 10, naznačen time što je dio R'-A-NR/R* spoja predstavljen formulom R'-X(CH>),-NRR? gdje je X spojen na skupinu E i to je skupina CH, in je 2.
contacting the aqueous medium provided in step a) with the hydrophobised ground calcium carbonate and/or the hydrophobised precipitated calcium carbonate obtained in step d). 
dovođenje u kontakt vodenog medija iz koraka a) s hidrofobiziranim mljevenim kalcijevim karbonatom i/ili taloženim kalcijevim karbonatom dobivenim u koraku d).
Amisulpride for use according to claims 1 to 3, to be administered by rectal, intranasal, buccal, oral, transdermal, sublingual or inhaled administration. 
Amisulprid, namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se primjenjuje rektalnom, intranazalnom, bukalnom, oralnom, transdermalnom, sublingvalnom ili inhalacijskom primjenom.
comprises, together with the heteroatom, A, to which it is bonded, an alcohol, an ether, a thioether, a silyl ether, a silyl thioether, an ester, a thioester, an amide, a carbonate, a thiocarbonate, a carbamate, a thiocarbamate, a urea, a phosphate, a phosphate salt or a phosphate ester; 
sadrži, zajedno s heteroatomom, A, na koji je vezan, alkohol, eter, tioeter, silil eter, silil tioeter, ester, tioester, amid, karbonat, tiokarbonat, karbamat, tiokarbamat, urea, fosfat, fosfatna sol ili fosfatni ester;
The composition or vaccine of any one of claims 1-11 for use in a method of vaccinating an animal. The composition or vaccine of any one of claims 1-11 for use in a method of inducing a protective response in an animal comprising at least one administration of the composition or vaccine. 
Pripravak ili cjepivo prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen/o time, da se upotrebljava u postupku induciranja zaštitne reakcije kod životinje, protiv NDV i opcionalno, protiv jednog ili više daljnjih ptičjih patogena, pri čemu taj postupak obuhvaća najmanje jednu primjenu pripravka ili cjepiva.
The composition for use as claimed in claim 1, wherein the cell-free supernatant is dialyzed, lyophilized and reconstituted in a buffer or wherein the cell-free supernatant is dialyzed, desiccated and reconstituted in a buffer. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se bestanični supernatant dijalizira, liofilizira i rekonstituira u puferu ili što se bestanični supernatant dijalizira, suši i rekonstituira u puferu.
The casting belt according to claim 12, wherein the casting belt (12, 14) has a yield strength of at least 100 MPa. 
Remen za lijevanje prema zahtjevu 12, naznačen time da remen za lijevanje (12, 14) ima granicu razvlačenja od barem 100 MPa.
The drain assembly according to claim 1, wherein the distance between the first planar surface and the second planar surface is less than 20 mm. 
Sifon za mirise (100) sukladno bilo kojem od prethodnih zahtjeva, naznačen time da je udaljenost između prve ravne površine i druge ravne površine manja od 20 mm.
The conjugate according to claim 4, wherein said peptide or said peptidomimetic is linked to the Cell Penetrating Peptide through a linker. 
Konjugat u skladu s patentnim zahtjevom 4, pri čemu je navedeni peptid ili peptidomimetik putem poveznika povezan s peptidom koji penetrira u stanicu.
Method according to claim 1 or 2 further characterized in that said concentrator (C) determines the amount (L) of said periodically measured and stored consumption related data also on the basis of parameters, especially a time interval, previously stored in said concentrator (C) from a centralized management facility (AMM). 
Metoda prema patentnom zahtjevu 1 ili 2 koja je nadalje naznačena time da navedeni sabirnik (C) određuje količinu (L) navedenih periodički izmjerenih i pohranjenih podataka vezanih uz potrošnju i na temelju parametara, posebno vremenskog intervala, prethodno pohranjenih u navedenom sabirniku (C) iz središnje upravljačke jedinice (AMM).
bit stream separating means for separating a bit stream that includes the encoded speech signal into an encoded bit stream, Spectral Band Replication (SBR) supplementary information and temporal envelope supplementary information, the bit stream received from outside the speech decoding device; 
separator struje bitova za razdvajanje struje bitova koja sadrži kodirani govorni signal na kodiranu struju bitova i dodatne informacije o vremenskoj ovojnici, gdje struja bitova dolazi izvan naprave za dekodiranje govora;
Rats were housed in groups of 5 under standard laboratory conditions under a 12hr light:dark cycle, lights on at 0700 hr. 
Å takori su smješteni u skupinama po 5 uz standardne laboratorijske uvjete uz 12 satnu izmjenu svjetlo-tama, svjetlo je uključivano u 7 sati ujutro.
EXAMPLE 3: Statistical Validation of the Multiplex Immunoassay 
Datum podnošenja europske prijave patenta:
is 0, or 1 and when s is 0 then a direct bond is intended; 
tjeQili 1ikada tje 0 tada je namjeravana direktna veza;
a polysaccharide, said polysaccharide having a polymer chain, said polymer chain being composed principally of fructose units linked together by B(2→1) glycosidic bonds at the anomeric C2, said polysaccharide being characterised by a degree of polymerisation, said degree of polymerisation being the number of monomer units in said polymer chain; 
polisaharid, pri čemu spomenuti polisaharid ima polimerni lanac, i spomenuti polimerni lanac se u suštini sastoji od fruktoznih jedinica koje su međusobno povezane s B(2→1) glikozidnim vezama na anomernom C2, pri čemu je spomenuti polisaharid naznačen sa stupnjem polimerizacije, i spomenuti stupanj polimerizacije je broj monomernih jedinica u spomenutom polimernom lancu;
The process according to claim 3, wherein the conversion of the compound of formula (IV) into the compound of formula (V) is carried out by means of the action of a sulphonyl chloride. 
Postupak za industrijsku sintezu spoja formule (1) u skladu s patentnim zahtjevom 3, naznačen time, da se pretvaranje spoja formule (IV) u spoj formule (V) izvodi djelovanjem sulfonil klorida.
X is oxygen, nitrogen or sulfur 
X je kisik, dušik ili sumpor,
Pharmaceutically acceptable salts are those in which the counter ions do not contribute significantly to the physiological activity or toxicity of the compounds and as such function as pharmacological equivalents. 
Farmaceutski prihvatljive soli su one u kojima protuioni značajno ne doprinose fiziološkoj aktivnosti ili toksičnosti spojeva i kao takve funkcioniraju kao farmakološki ekvivalenti.
The conjugate according to claim 9, wherein the reactive group is selected from the group consisting of an aldehyde group, a propionaldehyde group, a butyraldehyde group, a maleimide group and a succinimide derivative. 
Konjugat prema zahtjevu 12, naznačen time da je reaktivna skupina odabrana iz aldehidne skupine, propionaldehidne skupine, butiraldehidne skupine, maleimidne skupine ili derivata sukcinimida.
The resulting mixture was stirred at room temperature under nitrogen atmosphere for 3h. 
Dobivenu smjesu miješa se 3 sata na sobnoj temperaturi u atmosferi dušika.
UK 2 284 158 discloses an injection catheter consisting of an outer sheath and a needle means located in and axially movable with relation to the outer sheath. 
UK 2 284 158 otkriva kateter za injektiranje koji se sastoji od vanjskog omotača i sredstva za probadanje, koje sredstvo je smješteno u omotač, 1 sredstvo za probijanje se može aksijalno pomicati u odnosu na vanjski omotač.
The compound according to claim 1, wherein the compound of formula (I) is a compound of formula (IB): or a pharmaceutically acceptable salt thereof; wherein, 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je spoj formule (1) spoj formule (IB): R, Ra
The use or composition of claims 60 and 61, wherein the cytotoxic conjugate comprises a humanized version of the murine antibody DS6 or an epitope-binding fragment thereof as the cell binding agent and a taxane as the cytotoxic agent. 
Uporaba ili smjesa prema zahtjevima 60 i 61, naznačena time što citotoksični konjugat obuhvaća humaniziranu verziju mišjeg protutijela DS6 ili njegov fragment koji se veže za epitop kao tvar koja se veže za stanicu te taksan kao citotoksičnu tvar.
A said pharmaceutical composition can be prepared by mixing and processing an M3 antagonist of the invention, a PDE4 inhibitor and optionally other additives and/or carriers by methods known per se. 
Navedeni farmaceutski pripravak može se pripraviti miješanjem i obradom M3 antagonista sukladno predmetnom izumu, B2-agonista i po izboru drugih pomoćnih tvari i/ili nosača postupcima koji su poznati perse.
The difference in crystal structure can lead to differences in physicochemical parameters such as stability, rate of dissolution, bioavailability, and the like. 
Razlika u kristalnoj strukturi može dovesti do razlike u fizičko-kemijskim čimbenicima kao što su stabilnost, stopa otapanja, biodostupnost, i slično.
The system according to claim 13, wherein the hydrogel is a co-polymer of polysulfonate and acrylic acid. 
hidrogel je kopolimer. Sustav prema patentnom zahtjevu 10 dio (c), naznačen time što je hidrogel kopolimer polisulfata i akrilne kiseline.
Aspect 50. The method according to aspect 41, wherein said azo dye is chosen from methyl violet, neutral red, para red, amaranth, carmoisine, allura red AC, tartrazine, orange G, ponceau 4R, methyl red, and murexide-ammonium purpurate. 
Upotreba u skladu s patentnim zahtjevom 6, naznačena time što se navedeno azo bojilo bira između metilnog ljubičastog, neutralnog crvenila, para crvenila, amaranta, azorubina, alura crvenila AC, tartrazina, narančastog G, košenilovog crvenila 4R, metilnog crvenila, te mureksid-amonijevog purpurata.
Ophthalmic preparation in the form of eyedrops comprising a Brain-Derived Neurotrophic Factor (BDNF) in a concentration of at least 15 µg/µl. 
Oftalmološki pripravak u obliku kapi za oči, naznačen time da sadrži neurotropički faktor porijeklom iz mozga (BDNE, engl. brain-derived neurotrophic factor) u koncentraciji od najmanje 15 ug/uL.
stripping said extracted iron from said first organic solvent using one of water and a dilute acid; 
uklanjanje (275) spomenutog ekstrahiranog željeza iz spomenutog prvog organskog otapala koristeći jedno od vode i razrijeđene kiseline;
Fig. 9 shows a schematic section view of the beam-like block of wood being shown in Fig. 8; 
Slika 9 = prikazuje shematski pogled na presjek bloka od drva koji ima oblik grade i koji je prikazan na slici 8;
a polymerase selected from the group consisting of rhinovirus, polio, measles, Ebola, Coxsackie, West Nile, small pox, yellow fever, Dengue fever, influenza A, influenza B, lassa, lymphocytic choriomeningitis, Junin, Machupo, guanarito, hantavirus, Rift Valley Fever, La Crosse, California encephalitis, Crimean-Congo, Marburg, Japanese encephalitis, Kyasanur Forest, Venezuelan equine encephalitis, Eastern equine encephalitis, Western equine encephalitis, severe acute respiratory syndrome (SARS), parainfluenza, respiratory syncytial, Punta Toro, Tacaribe, and Pichinde viral polymerases. 
polimeraza odabrana iz skupine koja se sastoji od virusnih polimeraza rinovirusa, polio virusa, virusa morbila, Ebola virusa, Koksaki virusa, virusa Zapadnog Nila, virusa ospica, virusa žute groznice, virusa Denga groznice, virusa influence A, virusa influence B, Lassa virusa, virusa limfocitnog koriomeningitisa, Junin virusa, Machupo virusa, Guanarito virusa, hantavirusa, virusa groznice doline Rift, La Kros virusa, virusa kalifornijskog encefalitisa, virusa krimsko-kongoanske hemoragijske groznice, Marburg virusa, virusa japanskog encefalitisa, virusa šume Kyasanur, virusa venecuelanskog konjskog encefalitisa, virusa istočnog konjskog encefalitisa, virusa zapadnog konjskog encefalitisa, virusa teškog akutnog respiratornog sindroma (SARS), parainfluenca virusa, respiratornog sincicijalnog virusa, Punta Toro virusa, Takaribe virusa i Pichinde virusa.
server-side monitoring the quality of the transmitted audio signal. 
praćenja kvalitete prenesenog audio signala sa strane poslužitelja.
providing of a monoclonal antibody against the relevant vitamin D metabolites; 
(d) dodavanja monoklonskog protutijela za relevantne metabolite vitamina D;
A compound of formula I wherein 
Spoj formule I naznačen time, da
The filter according to claim 1, in which the cavities are significantly longer in a direction parallel to the side face than they are wide in a direction perpendicular to the side face. 
Filtar prema zahtjevu 7 ili 8, gdje su šupljine značajno dulje u smjeru paralelnom bočnoj strani, nego što su široke u smjeru okomitom na bočnu stranu.
A method for preparing the formulation according to the invention, comprises the steps of: Dissolving (or suspending) either dimethyl fumarate and optionally a rate-controlling agent in the form of a polymeric matrix material in water to obtain an aqueous suspension thereof; 
Postupak za pripravljanje formulacije prema bilo kojem zahtjevu od 1 do 16, naznačen time, da obuhvaća sljedeće korake: a) otapanje ili zaustavljanje sredstva za kontrolu učestalosti u obliku materijala polimernog matriksa u vodi za dobivanje njegove vodene otopine;
the antibody molecule or pharmaceutical composition is administered at a dose of about 1 to 30 mg/kg or at a dose of about 1 to 5 mg/kg; and/or wherein the antibody molecule or the pharmaceutical composition is administered once a week to once every 2, 3, or 4 weeks. 
molekula protutijela, ili farmaceutski pripravak se primjenjuje u dozi od oko 1 do 30 mg/kg ili u dozi od oko 1 do 5 mg/kg; i/ili pri čemu se molekula protutijela, ili farmaceutski pripravak se primjenjuje jednom tjedno do jednom svake 2, 3 ili 4 tjedana.
According to another embodiment, the aqueous slurry of the ball-shaped surface modified calcium carbonate containing mineral obtained by the process as herein described can be further dried to obtain a dry ball-shaped surface modified calcium carbonate containing mineral. 
Površinski modificirani kalcijev karbonat koji sadrži mineral koji je dobiven sušenjem vodene suspenzije prema bilo kojem od zahtjeva 16 do 20, naznačen time da navedeni površinski modificirani kalcijev karbonat koji sadrži mineral ima BET specifičnu dodirnu površinu veću od 15 m'/g.
one or more substitutions of an amino acid by a corresponding non-natural amino acid, whereby said corresponding non-natural amino acid is a derivative of the reference natural amino acid; and/or 
jednu ili više supstitucija aminokiseline odgovarajućom neprirodnom aminokiselinom, pri čemu je navedena odgovarajuća neprirodna aminokiselina derivat referentne prirodne aminokiseline; i/ili
A further benefit from the present invention is the relative lack of ash produced during use in comparison to ash from a conventional cigarette. 
Daljnja prednost od poželjnih realizacija iz sadašnjeg izuma je relativan nedostatak pepela koji se proizvodi za vrijeme korištenja u usporedbi sa pepelom iz konvencionalne cigarete.
Thus, the actual dosage regimen employed may vary widely and therefore may deviate from a preferred dosage regimen and one skilled in the art will recognize that dosage and dosage regimen outside these typical ranges can be tested and, where appropriate, can be used in the methods of this invention. 
Tako, korišten dozirni režim može varirati u širokom rasponu i može odstupati od poželjnog dozirnog režima te će stručnjak iz struke prepoznati dozu i dozirni režim izvan tih uobičajenih raspona i testirati ga, te kada je to odgovarajuće, koristiti ga u postupcima prema prikazanom izumu.
The solid oral extended release pharmaceutical dosage form of any one of claims 1 to 5, wherein the active agent is oxycodone hydrochloride and wherein a dosage form comprising 10 mg of oxycodone hydrochloride when tested in a comparative clinical study is bioequivalent to a reference tablet containing 10 mg of oxycodone hydrochloride in a matrix formulation containing: 
Farmaceutski oblik za doziranje s produljenim otpuštanjem u krutom obliku prema zahtjevu 1, naznačen time da je aktivni agens oksikodon hidroklorid i pri čemu je oblik za doziranje koji sadrži 10 mg oksikodon hidroklorida kada je testiran u usporednoj kliničkoj studiji bioekvivalentan referentnoj tableti koja sadrži 10 mg oksikodon hidroklorida u formulaciji matrice koja sadrži:
Fixed combination, non-fixed combination or kit of parts comprising at least one of the compounds or stereoisomers of the compounds according to any of claims 1 to 8, at least one therapeutic agent selected from the group consisting of corticosteroids, anticholinergics, B2-adrenoceptor agonists, H1 receptor antagonists, leukotriene receptor antagonists, type 5 phosphodiesterase inhibitors, HMG-CoA reductase inhibitors, lung surfactants, antibiotics and anti-diabetic agents, and at least one pharmaceutically acceptable auxiliary. 
Fiksirana kombinacija, nefiksirana kombinacija ili garnitura od segmenata, naznačena time, da obuhvaća barem jedan od spojeva ili stereoizomera spoja prema bilo kojem od zahtjeva 1 do 8, barem jedno terapeutsko sredstvo odabrano iz skupine koju čine kortikosteroidi, antikolinergici, agonisti B2-adrenoceptora, antagonisti H1 receptora, antagonisti leukotrien receptora, inhibitori fosfodiesteraze tipa 5, inhibitori HMG-CoA reduktaze, plućni surfaktanti, antibiotici i antidijabetička sredstva, te barem jedno farmaceutski prihvatljivo pomoćno sredstvo.
The monoclonal antibody of claim 4 that is a F(ab')2, Fab, Fab' or Fv fragment. 
Monoklonsko protutijelo u skladu s patentnim zahtjevom 10, naznačen time, da je fragment F(ab')2, Fab, Fab' ili Fv.
a light chain comprising VL-VC, wherein said VL comprising SEQ ID NO:165 and VC is either kappa or lambda. 
laki lanac koji sadrži VL-VC, pri čemu navedeni VL sadrži SEQ ID NO: 165 i VC je ili kapa ili lambda.